Background Clozapine remains the most effective treatment for treatment resistant psychotic disorders but carries a rare risk of myocarditis that can be life threatening and complicates continuation. The rate of myocarditis varies between countries, likely reflecting the speed of clozapine titration. Evidence guiding rechallenge after suspected clozapine associated myocarditis is limited.